Direct Flow Medical Inc. announced positive two-year data from the DISCOVER CE Mark Trial studying its Direct Flow Medical Transcatheter Aortic Valve System at the EuroPCR conference in Paris, France. Demonstrating excellent patient outcomes with few complications, the two-year data were presented by Antonio Colombo, M.D., Ph.D., from the Ospedale San Raffaele in Milan, Italy.

There were several technology takeaway messages for the future of electrophysiology (EP) at the Heart Rhythm Society (HRS) 2015 meeting in Boston. 

PHS Technologies Group LLC, a unit of PACSHealth LLC announced that Dell Healthcare and Life Sciences will become a marketing, distribution and hosting partner for its DoseMonitor OnLine software solution.

The Phase C results of the ProMRI Clinical Study were presented at the late-breaking clinical trial session of the Heart Rhythm Society (HRS) 2015 meeting. 

cardiomems, st. jude medical, heart failure

Important new data presented during the Heart Rhythm Society's (HRS) 36th annual Scientific Session supporting improved outcomes and cost-effectiveness of the CardioMEMS HF System for the management of Class III heart failure patients.

Biotronik announced that since the launch of the ProMRI Eluna pacemaker system in late March 2015, 60 percent of pacing devices sold by the company are approved for use during magnetic resonance imaging (MRI) scans. The announcement was made at Heart Rhythm 2015, the Heart Rhythm Society’s 36th annual scientific sessions, May 13-16 in Boston.

The Heart Rhythm Society (HRS) has released a first-of-its-kind expert consensus statement on three specific cardiovascular disorders that also involve the autonomic nervous system. The 2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope was written by an international group of experts and published online in HeartRhythm Journal, the official journal of HRS. The expert consensus statement was presented at Heart Rhythm 2015, the Heart Rhythm Society’s 36th annual scientific sessions.

Janssen Pharmaceuticals Inc. and its development partner Bayer HealthCare announced results from the VENTURE-AF trial. The study explored the potential of once-daily Xarelto (rivaroxaban) as an alternative to vitamin K antagonists (VKA), used to reduce the risk of blood clots, in people with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation, a frequently used interventional procedure to remove abnormal tissue in the heart that is causing the irregular heartbeat. The results were presented at Heart Rhythm 2015, the Heart Rhythm Society's 36th annual scientific sessions, and published in the European Heart Journal.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now